Bryostatin-1 benefits in severe Alzheimer's
disease patients were statistically significant with respect to
placebo at p < 0.007
NEW
YORK, Dec. 19, 2023 /PRNewswire/ --
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the
"Company"), an emerging biopharmaceutical company developing
therapeutics for neurodegenerative disorders, today announced that
its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the
International Association of Biomedical Sciences for his
presentation at the University of Southern
California-sponsored IABS Forum-2023, a gathering of
world-renowned neuroscientists and academics discussing "New
Concepts for the Treatment of Neurodegenerative Disorders."
The award was presented by Giulio Maria
Pasinetti, M.D., Ph.D., Saunders Family Chair and Professor
of Neurology at the Icahn School of Medicine at Mount Sinai, lead spokesperson for the event.
Dr. Alkon was congratulated for his cutting-edge research in drug
discovery and recognized for his decades of directing programs on
the molecular and structural basis of associative memory at the
National Neurologic Institute of the National Institutes of Health
(NIH).
Dr. Alkon's presentation, titled "Chronic Alzheimer's Disease
(AD) Patients Show Safe, Significant, and Persistent Benefit in
10-Month Bryostatin Trial," explored clinical data from the
Company's NIH-sponsored, Phase 2 trial of its lead therapeutic
candidate as a treatment for severe AD patients. In the trial,
secondary efficacy endpoints were met with statistically
significant benefits, p < 0.007, for severe AD patients. No
significant cognitive decline was observed throughout the 10-month
study, and persistent benefits continued at least 16 weeks beyond
the final dosing.
Dr. Pasinetti commented, "We were thrilled that Dr. Alkon,
recognized globally as a pioneer in research on brain-based neural
networks, the molecular basis of memory and degenerative brain
disorders, was able to join us and present at this conference. Dr.
Alkon discussed how, in pre-clinical studies, Bryostatin-1, MW 904,
an activator of PKC epsilon – BDNF pathways, demonstrated
synaptogenic, anti-apoptotic, anti-amyloid, and anti-tau tangle
efficacies…." Dr. Pasinetti noted, Bryostatin-1 has the potential
to be a promising new treatment for Alzheimer's disease, with
potential efficacy extending beyond chronic management to
addressing the underlying neurodegenerative consequences of chronic
AD progression.
IABS Forum-2023, held December 7-8,
2023 in Irvine, California,
was co-sponsored by the University of Southern
California (USC) School of
Pharmacy and the International Association of Biomedical
Sciences.
About Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that
has historically worked to develop novel therapies
for neurodegenerative diseases. Synaptogenix has conducted
clinical and preclinical studies of its lead therapeutic candidate,
Bryostatin-1, in Alzheimer's disease. Preclinical studies have also
demonstrated bryostatin's regenerative mechanisms of action for the
rare disease Fragile X syndrome, and for other neurodegenerative
disorders such as multiple sclerosis, stroke, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Synaptogenix for Bryostatin-1 as a treatment
for Fragile X syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its
website: www.synaptogen.com
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the anticipated Phase 1 trial of Bryostatin-1 in multiple
sclerosis. Such forward-looking statements are subject to risks and
uncertainties and other influences, many of which the Company has
no control over. There can be no assurance that the clinical
program for Bryostatin-1 will be successful in demonstrating safety
and/or efficacy, that the Company will not encounter problems or
delays in clinical development, or that Bryostatin-1 will ever
receive regulatory approval or be successfully commercialized.
Actual results and the timing of certain events and circumstances
may differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Additional
factors that may influence or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing,
the significant length of time associated with drug development and
related insufficient cash flows and resulting illiquidity, the
Company's patent portfolio, the Company's inability to expand its
business, significant government regulation of pharmaceuticals and
the healthcare industry, lack of product diversification,
availability of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the Company's
failure to implement its business plans or strategies. These and
other factors are identified and described in more detail in the
Company's filings with the Securities and Exchange Commission. The
Company does not undertake to update these forward-looking
statements.
Contact
800-811-5591
ir@synaptogen.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/synaptogenix-president-daniel-l-alkon-md-honored-for-scientific-presentation-at-usc-sponsored-forum-on-age-related-diseases-and-neurodegenerative-disorders-302018822.html
SOURCE Synaptogenix, Inc.